72869-16-0

Pramiracetam sulfate, together with aniracetam are two nootropics of the piracetam family introduced in 1993 for the treatment of attention and memory disorders resulting from degenerative or vascular disorders in the elderly. In patients with mild to moderate primary degenerative dementia, treatment with 75-300 mg/day of pramiracetam reduced depression,anxiety, sleep disturbance, and hostility with no observable adverse reactions. Significant improvement of performance on measures of memory, especially delayed recall, have been observed for pramiracetam treated patients with brain injury.

Warner-Lambert (U.S.A.)

Cognition adjuvant.

Pramiracetam Sulfate is a nootropic and a cognition activator drug. It also increases the rate of learning of complex visual discrimination problems in young, normal rhesus monkeys.

Remen; Neupramir; Prarnistar